Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma

计划入组 53 人 · 首次发布于 2015 年 9 月 28 日

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

计划入组 53 人 · 首次发布于 2012 年 9 月 11 日

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

计划入组 214 人 · 首次发布于 2010 年 11 月 1 日

Vemurafenib(Zelboraf)

C₂₃H₁₈ClF₂N₃O₃S · Rx

BRAF-V600E degrader

DPX BRAF/CPA

Cogent Biosciences

United States

BRAC UNIVERSITY

Bangladesh

Nuvation Bio

United States

BRAF p.V600E Mutation Shows Limited Prognostic Value in Papillary Thyroid Cancer Risk Stratification

BEAVER Trial Demonstrates Efficacy of Binimetinib-Encorafenib Combination in Advanced Non-V600E BRAF-Mutated Tumors

BRAF Status and Response Kinetics Guide First-line Immunotherapy Selection in Advanced Melanoma